Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Replimune securities between November 22, 2024, and July 21, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, resulting in the FDA deeming the trial inadequate [3]. Investor Information - Investors who suffered losses or have questions regarding their rights are encouraged to contact the law firm for more information [4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about their claims [4]. Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate versions of the weight-loss drug Wegovy [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices that jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Specific allegations include the failure to disclose that Hims was promoting illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that Hims misrepresented the nature of its collaboration with Novo Nordisk, suggesting that it would ensure continued access to Wegovy for Hims subscribers [4]. Group 3: Investor Communication - Investors who suffered losses or have information related to the case are encouraged to contact the law firm Bragar Eagel & Squire for further assistance [5]. - The law firm specializes in representing individual and institutional investors in complex litigation [6].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in cGMP compliance at a third-party vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4][5]

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding the quality of care provided at its facilities and undisclosed risks associated with child abuse incidents [3][4]. Company Overview - KinderCare Learning Companies, Inc. (NYSE: KLC) is facing legal action in the United States District Court District of Oregon on behalf of investors who purchased its IPOs [1]. - The lawsuit claims that the registration statement for the IPO was false and/or misleading, failing to disclose significant issues related to child care quality and safety [3]. Allegations - The lawsuit alleges that numerous incidents of child abuse, neglect, and harm occurred at KinderCare facilities [3]. - It is claimed that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry [3]. - The company is accused of being exposed to material risks, including lawsuits, regulatory actions, and reputational damage due to these undisclosed issues [3]. Stock Performance - Since the IPO, KinderCare's stock price has fallen to lows near $9 per share, indicating a significant decline in investor confidence [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - Investors have until August 25, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Sarepta - Sarepta is accused of making materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with a positive revenue outlook [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to recruitment halts and regulatory scrutiny [3]. Group 3: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock fell by $27.81 (27.44%) to close at $73.54 [4]. - After the announcement on April 4, 2025, regarding regulatory scrutiny, the stock dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, led to a further decline of $15.24 (42.12%) to close at $20.91 [4]. - The FDA's Safety Communication on June 24, 2025, resulted in a stock price decrease of $1.52 (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made false statements regarding the availability of branded Wegovy alongside its compounded products, which could mislead users and investors about the company's market position [4].

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly providing misleading statements about its business growth and performance during the class period from May 2, 2024, to May 6, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Vestis securities during the specified class period [1]. - Investors have until August 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Vestis - The complaint alleges that Vestis made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. - Specifically, it is claimed that Vestis would be unable to execute planned strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Group 3: Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [4]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [4]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [4].

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly providing misleading information to investors regarding its business growth and strategic initiatives [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Vestis securities between May 2, 2024, and May 6, 2025, with a deadline of August 8, 2025, to apply as lead plaintiff [1]. - The complaint alleges that Vestis made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. Group 2: Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrawing its revenue and growth guidance for the full fiscal year [4]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in customer volume [4]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Laser Photonics Corporation for possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure Issues - On September 23, 2024, Laser Photonics announced that its previously issued financial statements for the year ended December 31, 2023, and the quarter ended June 30, 2024, should no longer be relied upon due to an overstatement of deferred revenue identified by its predecessor auditor, Fruci & Associates II, PLLC [3]. - Following this announcement, Laser Photonics' stock price dropped by $6.90 per share, or 36.7%, closing at $11.90 per share on September 25, 2024 [3]. Legal Rights and Investor Support - Investors who purchased or acquired Laser Photonics shares and suffered losses are encouraged to contact Bragar Eagel & Squire for information regarding their legal rights and potential claims [1][4].